Epirus Biopharmaceuticals Stock Price, News & Analysis (OTCMKTS:EPRSQ)

$0.0035 0.00 (0.00 %)
(As of 02/22/2018 11:38 AM ET)
Previous Close$0.00
Today's Range$0.00 - $0.00
52-Week Range$0.00 - $0.03
Volume24,400 shs
Average Volume36,896 shs
Market Capitalization$90,000.00
P/E RatioN/A
Dividend YieldN/A
Beta1.28

About Epirus Biopharmaceuticals (OTCMKTS:EPRSQ)

EPIRUS Biopharmaceuticals, Inc. (Epirus) is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company's products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a); BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases; BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis; BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders.

Receive EPRSQ News and Ratings via Email

Sign-up to receive the latest news and ratings for EPRSQ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:EPRSQ
CUSIPN/A
Phone617-600-3497

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$580,000.00
Price / Sales0.16
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares26,180,000

Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Frequently Asked Questions

What is Epirus Biopharmaceuticals' stock symbol?

Epirus Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "EPRSQ."

How were Epirus Biopharmaceuticals' earnings last quarter?

Epirus Biopharmaceuticals Inc (OTCMKTS:EPRSQ) issued its quarterly earnings results on Tuesday, March, 15th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.56) by $0.07. The biopharmaceutical company had revenue of $0.29 million for the quarter, compared to the consensus estimate of $0.41 million. View Epirus Biopharmaceuticals' Earnings History.

Who are some of Epirus Biopharmaceuticals' key competitors?

Who are Epirus Biopharmaceuticals' key executives?

Epirus Biopharmaceuticals' management team includes the folowing people:

  • Robert Ticktin, Senior Vice President, General Counsel, Secretary (Age 53)
  • Vincent E. Aurentz, Chief Business Officer

How do I buy Epirus Biopharmaceuticals stock?

Shares of Epirus Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Epirus Biopharmaceuticals' stock price today?

One share of Epirus Biopharmaceuticals stock can currently be purchased for approximately $0.00.

How big of a company is Epirus Biopharmaceuticals?

Epirus Biopharmaceuticals has a market capitalization of $90,000.00 and generates $580,000.00 in revenue each year.

How can I contact Epirus Biopharmaceuticals?

Epirus Biopharmaceuticals' mailing address is 699 BOYLSTON ST 8TH FLOOR, BOSTON MA, 02116. The biopharmaceutical company can be reached via phone at 617-600-3497 or via email at [email protected]


MarketBeat Community Rating for Epirus Biopharmaceuticals (EPRSQ)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  44 (Vote Outperform)
Underperform Votes:  36 (Vote Underperform)
Total Votes:  80
MarketBeat's community ratings are surveys of what our community members think about Epirus Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Consensus Price Target History

Price Target History for Epirus Biopharmaceuticals (OTCMKTS:EPRSQ)

Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/15/2016Leerink SwannDowngradeOutperform -> Market PerformView Rating Details
5/11/2016BTIG ResearchDowngradeBuy -> NeutralView Rating Details
5/11/2016WedbushDowngradeOutperform -> Neutral$11.00 -> $2.00View Rating Details
(Data available from 2/22/2016 forward)

Earnings

Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Earnings History and Estimates Chart

Earnings by Quarter for Epirus Biopharmaceuticals (OTCMKTS:EPRSQ)

Epirus Biopharmaceuticals (OTCMKTS EPRSQ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2016Q1 2016($0.53)($0.66)$2.00 million$0.80 millionViewN/AView Earnings Details
3/15/2016Q415($0.56)($0.63)$0.41 million$0.29 millionViewListenView Earnings Details
11/16/2015Q315($0.51)($0.59)$221.00 millionViewListenView Earnings Details
8/7/2015Q215($0.38)($0.65)$0.40 million$0.05 millionViewN/AView Earnings Details
5/12/2015Q1($0.43)($0.39)$0.68 million$0.03 millionViewN/AView Earnings Details
3/23/2015Q414($0.99)($0.80)ViewN/AView Earnings Details
11/10/2014($0.43)($1.28)ViewN/AView Earnings Details
8/20/2014($1.20)($1.52)ViewN/AView Earnings Details
8/11/2014Q2 2014($1.20)($1.52)$1.50 million$1.13 millionViewN/AView Earnings Details
5/9/2014Q114$0.20($0.15)$9.00 million$1.60 millionViewN/AView Earnings Details
3/13/2014($0.14)($0.29)$3.20 million$3.77 millionViewN/AView Earnings Details
11/4/2013Q313($0.50)($0.46)$3.66 million$3.40 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.07)($0.08)$2.91 million$3.89 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.07)($0.06)$3.44 million$3.70 millionViewN/AView Earnings Details
3/6/2013Q4 2012($0.08)($0.06)$3.12 million$3.67 millionViewN/AView Earnings Details
11/8/2012Q3 2012($5.40)($6.00)ViewN/AView Earnings Details
8/7/2012Q2 2012($6.60)($5.46)ViewN/AView Earnings Details
5/3/2012Q1 2012($6.60)($7.20)ViewN/AView Earnings Details
3/7/2012Q4 2011($6.00)($6.00)ViewN/AView Earnings Details
11/2/2011Q3 2011($6.00)($5.58)ViewN/AView Earnings Details
8/3/2011Q2 2011($5.40)($6.84)ViewN/AView Earnings Details
5/4/2011Q1 2011($5.40)($7.20)ViewN/AView Earnings Details
3/9/2011Q4 2010($7.20)($8.04)ViewN/AView Earnings Details
11/10/2010Q3 2010($6.60)($4.56)ViewN/AView Earnings Details
8/5/2010Q2 2010($5.82)ViewN/AView Earnings Details
5/6/2010Q1 2010$24.78ViewN/AView Earnings Details
3/25/2010Q4 2009$11.76ViewN/AView Earnings Details
11/3/2009Q3 2009($9.72)ViewN/AView Earnings Details
8/10/2009Q2 2009($6.60)($11.52)ViewN/AView Earnings Details
5/7/2009Q1 2009($10.80)($15.48)ViewN/AView Earnings Details
3/4/2009Q4 2008($26.99)($18.12)ViewN/AView Earnings Details
11/5/2008Q3 2008($23.40)($26.75)ViewN/AView Earnings Details
8/6/2008Q2 2008($25.79)($30.41)ViewN/AView Earnings Details
5/6/2008Q1 2008($24.60)($28.85)ViewN/AView Earnings Details
3/6/2008Q4 2007($26.99)($25.37)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Epirus Biopharmaceuticals (OTCMKTS:EPRSQ)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Epirus Biopharmaceuticals (OTCMKTS EPRSQ) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.06%
Insider Trades by Quarter for Epirus Biopharmaceuticals (OTCMKTS:EPRSQ)
Insider Trades by Quarter for Epirus Biopharmaceuticals (OTCMKTS:EPRSQ)

Epirus Biopharmaceuticals (OTCMKTS EPRSQ) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/21/2015Robert TicktinGeneral CounselBuy3,000$3.72$11,160.003,000View SEC Filing  
12/17/2015Aurentz VincentInsiderBuy2,200$3.43$7,546.002,200View SEC Filing  
12/16/2015Amit MunshiCEOBuy8,270$2.80$23,156.00View SEC Filing  
12/15/2015Amit MunshiCEOBuy8,069$2.87$23,158.03View SEC Filing  
12/9/2015Amit MunshiCEOBuy13,190$4.07$53,683.30View SEC Filing  
12/9/2015Aurentz VincentInsiderBuy2,800$3.85$10,780.00View SEC Filing  
9/21/2015Amit MunshiCEOBuy10,000$6.19$61,900.00View SEC Filing  
9/18/2015Amit MunshiCEOBuy10,000$5.99$59,900.00View SEC Filing  
2/6/2015Montreux Equity Partners Iv LpMajor ShareholderSell167,316$5.00$836,580.00View SEC Filing  
2/4/2015Montreux Equity Partners Iv LpMajor ShareholderSell52,684$4.98$262,366.32View SEC Filing  
2/4/2015Scott M RocklageDirectorBuy400,000$5.00$2,000,000.00View SEC Filing  
1/26/2015Montreux Equity Partners Iv LpMajor ShareholderSell38,516$6.47$249,198.52View SEC Filing  
1/23/2015Montreux Equity Partners Iv LpMajor ShareholderSell22,530$6.29$141,713.70View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Epirus Biopharmaceuticals (OTCMKTS EPRSQ) News Headlines

Source:
No headlines for this company have been tracked by MarketBeat.com

SEC Filings

Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Epirus Biopharmaceuticals (OTCMKTS EPRSQ) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.